2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy
Identifieur interne : 002553 ( Istex/Corpus ); précédent : 002552; suivant : 0025542.3. Rheumatoid arthritis ‐ anti‐TNFα therapy
Auteurs :Source :
- International Journal of Rheumatic Diseases [ 1756-1841 ] ; 2010-07.
English descriptors
- Teeft :
- Acid phosphatase, Adalimumab, Adverse event, Adverse events, American college, Ankylosing, Ankylosing spondylitis, Arthritis, Asia league, Assay, Baseline, Baseline characteristics, Basic therapy, Biologic, Biologic agents, Biologic therapy, Biological agents, Biological therapy, Biological treatment, Biologics, Biologics treatment, Bone destruction, Bone metabolism, Bone turnover markers, Change therapy country, China objective, Clinical characteristics, Clinical disease activity, Clinical examination, Clinical practice, Clinical remission, Clinical response, Combination therapy, Concomitant methotrexate, Consulting speaker, Control period, Conventional dmards, Current study, Cutaneous induration, Cutoff value, Cytokine, Discontinuation, Disease activity, Disease activity score, Disease duration, Dmard, Dmards, Dmards group, Dmards maintenance therapy, Dose reduction, Erythrocyte sedimentation rate, Etanercept, Eular, Eular response, European league, Evaluable patients, Exact test, First hospital, Golimumab, Good response, Guang china, Gunma university, Health assessment questionnaire, Healthy control subjects, Healthy controls, Herpes zoster, High disease activity, Hong kong, Hospital selayang, Immunosorbent assay, Inadequate response, Indeterminate results, Induration diameter, Infection, Infusion, Infusion reaction, Infusion reactions, Injection site reaction, Injection site reactions, International journal, Isoniazid prophylaxis, Japan objective, Juvenile idiopathic arthritis, Kappa value, Knee joints, Large joints, Last observation, Latent tuberculosis infection, Liberation army, Ltbi, Lumbar spine, Major concern, Malaysia, Malaysia background, Malaysia objective, Medical records, Medical university, Medicamentous remission, Methotrexate, Mitsubishi tanabe pharma corporation, Monitoring tuberculosis, Morning stiffness, Multicenter study, Necrosis factor, Normal liver function, Observational study, Operative synovectomy, Orthopaedic surgery, Orthopedic surgery, Other group, Other parameters, Palo alto, Past history, Patient characteristics, Pdus parameters, Perioperative period, Peripheral blood, Petaling jaya, Physical function, Polymorphism, Power doppler ultrasonography, Preoperative, Present study, Primary endpoint, Progression, Psoriatic arthritis, Pulmonary congestion, Pulmonary hypertension, Quantiferon test, Radiographic, Radiographic progression, Regression analysis, Relapsing, Relapsing synovitis, Remark study, Remission, Responder, Retrospective review, Retrospective study, Rheumatic, Rheumatic diseases, Rheumatic patients, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatoid factor, Rheumatology, Risk factors, Safety data, Safety signals, Screening dose, Second patient, Second xiangya hospital, Serum level, Serum levels, Sharp score, Site infection, Spondylitis, Stable remission, Standardized uptake value, States objective, Study agent, Suppl, Synovial, Synovitis, Tender joints, Therapy, Tnfa, Tnfa therapy, Tnfa therapy results, Total count, Treg cells, Tuberculous, Tuberculous infection, Tuberculous infections, Tumor necrosis factor, Unmet need, Usual antirheumatic drugs, Usual dmard therapy, Various pros, Vdhs changes, Wound healing, Xijing hospital, Yearly changes.
Url:
DOI: 10.1111/j.1756-185X.2010.01498.x
Links to Exploration step
ISTEX:ABCA6AAAD9F3C6F09F7FA20152E8ECBB2ED9DBE6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:ABCA6AAAD9F3C6F09F7FA20152E8ECBB2ED9DBE6</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1756-185X.2010.01498.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-G6MPTG3H-Z/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002553</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002553</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy</title></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="sub">14th Congress of Asia Pacific League of Associations for Rheumatology, 11‐15 July 2010, Hong Kong Convention and Exhibition Centre</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="ISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><imprint><biblScope unit="vol">13</biblScope><biblScope unit="issue">s1</biblScope><biblScope unit="page" from="85">85</biblScope><biblScope unit="page" to="94">94</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-07">2010-07</date></imprint><idno type="ISSN">1756-1841</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1756-1841</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acid phosphatase</term><term>Adalimumab</term><term>Adverse event</term><term>Adverse events</term><term>American college</term><term>Ankylosing</term><term>Ankylosing spondylitis</term><term>Arthritis</term><term>Asia league</term><term>Assay</term><term>Baseline</term><term>Baseline characteristics</term><term>Basic therapy</term><term>Biologic</term><term>Biologic agents</term><term>Biologic therapy</term><term>Biological agents</term><term>Biological therapy</term><term>Biological treatment</term><term>Biologics</term><term>Biologics treatment</term><term>Bone destruction</term><term>Bone metabolism</term><term>Bone turnover markers</term><term>Change therapy country</term><term>China objective</term><term>Clinical characteristics</term><term>Clinical disease activity</term><term>Clinical examination</term><term>Clinical practice</term><term>Clinical remission</term><term>Clinical response</term><term>Combination therapy</term><term>Concomitant methotrexate</term><term>Consulting speaker</term><term>Control period</term><term>Conventional dmards</term><term>Current study</term><term>Cutaneous induration</term><term>Cutoff value</term><term>Cytokine</term><term>Discontinuation</term><term>Disease activity</term><term>Disease activity score</term><term>Disease duration</term><term>Dmard</term><term>Dmards</term><term>Dmards group</term><term>Dmards maintenance therapy</term><term>Dose reduction</term><term>Erythrocyte sedimentation rate</term><term>Etanercept</term><term>Eular</term><term>Eular response</term><term>European league</term><term>Evaluable patients</term><term>Exact test</term><term>First hospital</term><term>Golimumab</term><term>Good response</term><term>Guang china</term><term>Gunma university</term><term>Health assessment questionnaire</term><term>Healthy control subjects</term><term>Healthy controls</term><term>Herpes zoster</term><term>High disease activity</term><term>Hong kong</term><term>Hospital selayang</term><term>Immunosorbent assay</term><term>Inadequate response</term><term>Indeterminate results</term><term>Induration diameter</term><term>Infection</term><term>Infusion</term><term>Infusion reaction</term><term>Infusion reactions</term><term>Injection site reaction</term><term>Injection site reactions</term><term>International journal</term><term>Isoniazid prophylaxis</term><term>Japan objective</term><term>Juvenile idiopathic arthritis</term><term>Kappa value</term><term>Knee joints</term><term>Large joints</term><term>Last observation</term><term>Latent tuberculosis infection</term><term>Liberation army</term><term>Ltbi</term><term>Lumbar spine</term><term>Major concern</term><term>Malaysia</term><term>Malaysia background</term><term>Malaysia objective</term><term>Medical records</term><term>Medical university</term><term>Medicamentous remission</term><term>Methotrexate</term><term>Mitsubishi tanabe pharma corporation</term><term>Monitoring tuberculosis</term><term>Morning stiffness</term><term>Multicenter study</term><term>Necrosis factor</term><term>Normal liver function</term><term>Observational study</term><term>Operative synovectomy</term><term>Orthopaedic surgery</term><term>Orthopedic surgery</term><term>Other group</term><term>Other parameters</term><term>Palo alto</term><term>Past history</term><term>Patient characteristics</term><term>Pdus parameters</term><term>Perioperative period</term><term>Peripheral blood</term><term>Petaling jaya</term><term>Physical function</term><term>Polymorphism</term><term>Power doppler ultrasonography</term><term>Preoperative</term><term>Present study</term><term>Primary endpoint</term><term>Progression</term><term>Psoriatic arthritis</term><term>Pulmonary congestion</term><term>Pulmonary hypertension</term><term>Quantiferon test</term><term>Radiographic</term><term>Radiographic progression</term><term>Regression analysis</term><term>Relapsing</term><term>Relapsing synovitis</term><term>Remark study</term><term>Remission</term><term>Responder</term><term>Retrospective review</term><term>Retrospective study</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatic patients</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatoid factor</term><term>Rheumatology</term><term>Risk factors</term><term>Safety data</term><term>Safety signals</term><term>Screening dose</term><term>Second patient</term><term>Second xiangya hospital</term><term>Serum level</term><term>Serum levels</term><term>Sharp score</term><term>Site infection</term><term>Spondylitis</term><term>Stable remission</term><term>Standardized uptake value</term><term>States objective</term><term>Study agent</term><term>Suppl</term><term>Synovial</term><term>Synovitis</term><term>Tender joints</term><term>Therapy</term><term>Tnfa</term><term>Tnfa therapy</term><term>Tnfa therapy results</term><term>Total count</term><term>Treg cells</term><term>Tuberculous</term><term>Tuberculous infection</term><term>Tuberculous infections</term><term>Tumor necrosis factor</term><term>Unmet need</term><term>Usual antirheumatic drugs</term><term>Usual dmard therapy</term><term>Various pros</term><term>Vdhs changes</term><term>Wound healing</term><term>Xijing hospital</term><term>Yearly changes</term></keywords></textClass></profileDesc></teiHeader></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>etanercept</json:string><json:string>rheumatoid</json:string><json:string>rheumatoid arthritis</json:string><json:string>rheumatology</json:string><json:string>baseline</json:string><json:string>remission</json:string><json:string>biologics</json:string><json:string>disease duration</json:string><json:string>dmard</json:string><json:string>disease activity</json:string><json:string>dmards</json:string><json:string>rheumatic diseases</json:string><json:string>infusion</json:string><json:string>eular</json:string><json:string>arthritis</json:string><json:string>biologic agents</json:string><json:string>methotrexate</json:string><json:string>tnfa</json:string><json:string>synovitis</json:string><json:string>polymorphism</json:string><json:string>responder</json:string><json:string>malaysia</json:string><json:string>discontinuation</json:string><json:string>infusion reactions</json:string><json:string>asia league</json:string><json:string>golimumab</json:string><json:string>serum level</json:string><json:string>knee joints</json:string><json:string>suppl</json:string><json:string>cytokine</json:string><json:string>biologic</json:string><json:string>radiographic</json:string><json:string>adalimumab</json:string><json:string>ankylosing</json:string><json:string>spondylitis</json:string><json:string>ankylosing spondylitis</json:string><json:string>international journal</json:string><json:string>synovial</json:string><json:string>disease activity score</json:string><json:string>ltbi</json:string><json:string>eular response</json:string><json:string>relapsing</json:string><json:string>adverse events</json:string><json:string>rheumatoid arthritis patients</json:string><json:string>tuberculous</json:string><json:string>preoperative</json:string><json:string>adverse event</json:string><json:string>physical function</json:string><json:string>tnfa therapy</json:string><json:string>infusion reaction</json:string><json:string>radiographic progression</json:string><json:string>clinical response</json:string><json:string>erythrocyte sedimentation rate</json:string><json:string>bone metabolism</json:string><json:string>pulmonary hypertension</json:string><json:string>china objective</json:string><json:string>rheumatic</json:string><json:string>dmards group</json:string><json:string>relapsing synovitis</json:string><json:string>medical university</json:string><json:string>psoriatic arthritis</json:string><json:string>inadequate response</json:string><json:string>biologic therapy</json:string><json:string>mitsubishi tanabe pharma corporation</json:string><json:string>hong kong</json:string><json:string>biological therapy</json:string><json:string>wound healing</json:string><json:string>biological agents</json:string><json:string>bone destruction</json:string><json:string>orthopaedic surgery</json:string><json:string>therapy</json:string><json:string>assay</json:string><json:string>quantiferon test</json:string><json:string>guang china</json:string><json:string>immunosorbent assay</json:string><json:string>retrospective review</json:string><json:string>tumor necrosis factor</json:string><json:string>tuberculous infection</json:string><json:string>healthy controls</json:string><json:string>orthopedic surgery</json:string><json:string>healthy control subjects</json:string><json:string>other parameters</json:string><json:string>malaysia objective</json:string><json:string>latent tuberculosis infection</json:string><json:string>present study</json:string><json:string>japan objective</json:string><json:string>consulting speaker</json:string><json:string>current study</json:string><json:string>tuberculous infections</json:string><json:string>states objective</json:string><json:string>concomitant methotrexate</json:string><json:string>lumbar spine</json:string><json:string>multicenter study</json:string><json:string>progression</json:string><json:string>infection</json:string><json:string>exact test</json:string><json:string>usual dmard therapy</json:string><json:string>yearly changes</json:string><json:string>petaling jaya</json:string><json:string>safety data</json:string><json:string>dose reduction</json:string><json:string>unmet need</json:string><json:string>usual antirheumatic drugs</json:string><json:string>second xiangya hospital</json:string><json:string>screening dose</json:string><json:string>various pros</json:string><json:string>last observation</json:string><json:string>baseline characteristics</json:string><json:string>rheumatoid factor</json:string><json:string>american college</json:string><json:string>biologics treatment</json:string><json:string>health assessment questionnaire</json:string><json:string>rheumatic patients</json:string><json:string>major concern</json:string><json:string>xijing hospital</json:string><json:string>observational study</json:string><json:string>bone turnover markers</json:string><json:string>liberation army</json:string><json:string>patient characteristics</json:string><json:string>morning stiffness</json:string><json:string>palo alto</json:string><json:string>control period</json:string><json:string>good response</json:string><json:string>tnfa therapy results</json:string><json:string>malaysia background</json:string><json:string>clinical characteristics</json:string><json:string>vdhs changes</json:string><json:string>medical records</json:string><json:string>juvenile idiopathic arthritis</json:string><json:string>peripheral blood</json:string><json:string>second patient</json:string><json:string>isoniazid prophylaxis</json:string><json:string>clinical examination</json:string><json:string>european league</json:string><json:string>sharp score</json:string><json:string>high disease activity</json:string><json:string>combination therapy</json:string><json:string>total count</json:string><json:string>herpes zoster</json:string><json:string>perioperative period</json:string><json:string>study agent</json:string><json:string>large joints</json:string><json:string>clinical remission</json:string><json:string>power doppler ultrasonography</json:string><json:string>necrosis factor</json:string><json:string>clinical practice</json:string><json:string>monitoring tuberculosis</json:string><json:string>pdus parameters</json:string><json:string>cutaneous induration</json:string><json:string>site infection</json:string><json:string>kappa value</json:string><json:string>risk factors</json:string><json:string>retrospective study</json:string><json:string>regression analysis</json:string><json:string>past history</json:string><json:string>induration diameter</json:string><json:string>cutoff value</json:string><json:string>indeterminate results</json:string><json:string>conventional dmards</json:string><json:string>acid phosphatase</json:string><json:string>first hospital</json:string><json:string>serum levels</json:string><json:string>tender joints</json:string><json:string>biological treatment</json:string><json:string>stable remission</json:string><json:string>operative synovectomy</json:string><json:string>primary endpoint</json:string><json:string>medicamentous remission</json:string><json:string>basic therapy</json:string><json:string>evaluable patients</json:string><json:string>gunma university</json:string><json:string>standardized uptake value</json:string><json:string>hospital selayang</json:string><json:string>injection site reactions</json:string><json:string>normal liver function</json:string><json:string>remark study</json:string><json:string>dmards maintenance therapy</json:string><json:string>clinical disease activity</json:string><json:string>other group</json:string><json:string>change therapy country</json:string><json:string>pulmonary congestion</json:string><json:string>treg cells</json:string><json:string>injection site reaction</json:string><json:string>safety signals</json:string></teeft></keywords><articleId><json:string>APL1498</json:string></articleId><arkIstex>ark:/67375/WNG-G6MPTG3H-Z</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>abstract</json:string></originalGenre><qualityIndicators><score>7.012</score><pdfWordCount>14836</pdfWordCount><pdfCharCount>89862</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>595.276 x 779.528 pts</pdfPageSize><pdfWordsPerPage>1484</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>false</refBibsNative><abstractWordCount>1</abstractWordCount><abstractCharCount>0</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy</title><genre><json:string>abstract</json:string></genre><host><title>International Journal of Rheumatic Diseases</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1756-185X</json:string></doi><issn><json:string>1756-1841</json:string></issn><eissn><json:string>1756-185X</json:string></eissn><publisherId><json:string>APL</json:string></publisherId><volume>13</volume><issue>s1</issue><pages><first>85</first><last>94</last><total>4</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2009</json:string><json:string>2282</json:string><json:string>from May 2005 to December 2009</json:string><json:string>2006</json:string><json:string>1999</json:string><json:string>from January 2005 to December 2009</json:string><json:string>2008</json:string><json:string>2010</json:string><json:string>2004</json:string><json:string>From April 2005 to December 2006</json:string></date><geogName></geogName><orgName><json:string>Colombia Objective</json:string><json:string>China Objective</json:string><json:string>University of Penn</json:string><json:string>Research and Education</json:string><json:string>Abbott Japan Co</json:string><json:string>Astellas Pharma Inc.</json:string><json:string>People’s Hospital, Shanghai, China</json:string><json:string>Xiangya Hospital, Central South University, Changsha, China</json:string><json:string>General Health International Journal</json:string><json:string>Hospital of Sun Yat</json:string><json:string>Skovde Hospital, Skovde, Sweden</json:string><json:string>Department of Rheumatology, West China Medical School, Chengdu, China</json:string><json:string>Liberation Army, Beijing, China</json:string><json:string>Cebu Doctors Hospital, Cebu City, Philippines</json:string><json:string>Medical Center, Durham</json:string><json:string>University of Medicine</json:string><json:string>Military Medical University</json:string><json:string>Mass General Hospital/ Harvard Med School, Boston, MA, United States</json:string><json:string>Okayama University Hospital, Okayama, Japan Objective</json:string><json:string>Xinjiang People’s Hospital, Urumqi, China Objective</json:string><json:string>Guangdong Provincal People’s Hospital,Rhumatism Department</json:string><json:string>Hospital of Nanjing University, Nanjing, China</json:string><json:string>Development, Inc</json:string><json:string>Malaysia Objective</json:string><json:string>Johnson Pharmaceutical Research and Development, LLC, Horsham, PA, United States H SHEN, LP XIA</json:string><json:string>Hanyang University Hospital, Seoul, Korea</json:string><json:string>Xijing Hospital, Shaanxi, China</json:string><json:string>Xiangya Hospital, Central South University, Changsha, China Objective</json:string><json:string>Mitsubishi Tanabe Pharma Corporation</json:string><json:string>Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan Juvenile</json:string><json:string>Taisho Toyama Pharmaceutical Co.</json:string><json:string>Gunma University</json:string><json:string>Eisai Co.</json:string><json:string>Japan Objective</json:string><json:string>Okayama University</json:string><json:string>Chugai Pharmaceutical Co.</json:string><json:string>Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia</json:string><json:string>Clinical Research, Duncansville, PA, United States</json:string><json:string>United States Objective</json:string><json:string>Japan Hospital Tuanku Ja</json:string><json:string>Princess Margaret Hospital, HKSAR, Hong Kong</json:string><json:string>Hospital Selayang Malaysia</json:string><json:string>Clinical Hospital, Atlanta, GA, United States</json:string><json:string>Oklahoma Center</json:string><json:string>Inha University</json:string><json:string>General Hospital of the People</json:string><json:string>Actelion Pharmaceuticals Japan Ltd</json:string><json:string>Department of Rheumatology</json:string><json:string>Japan Background</json:string><json:string>Santen Pharmaceutical Co.</json:string><json:string>ZHU Department of Rheumatology</json:string><json:string>Princess Margaret Hospital, HKSAR, Hong Kong Objective</json:string><json:string>Development,Inc</json:string><json:string>XIAO Department of Rheumatology and Immunology</json:string><json:string>SRL Inc, Tokyo</json:string><json:string>United States, CHU Hopital Sud A Michallon, Echirolles, France</json:string><json:string>Xiangya Hospital, Central-South University, Changsha, China</json:string><json:string>Hospital, Sun Yat</json:string><json:string>Department of Rheumatology, Shanghai Jiaotong University Renji Hospital, Shanghai, China</json:string><json:string>Martina Hansens Hospital, Gjettum, Norway</json:string><json:string>Atlanta Center</json:string><json:string>Helsinki University Central Hospital, Helsinki, Finland</json:string><json:string>Department of Orthopaedic Surgery, Gunma University, Maebashi,Gunma, Japan, Diagnostic Radiology and Nuclear Medicine</json:string><json:string>United States Osaka City University Graduate School of Medicine, Osaka, Japan Objective</json:string><json:string>Hospital of Suzhou University, Suzhou, China Objective</json:string><json:string>Department of Rheumatology, Peking University People</json:string><json:string>Karolinska Institute, Stockholm, Sweden</json:string><json:string>University Hospital of Heraklion, Crete, Greece</json:string><json:string>ACR</json:string><json:string>Hietzing Hospital, Vienna, Austria</json:string><json:string>Romania Background</json:string><json:string>Mary’s Hospital, Seoul, Korea</json:string><json:string>Medical University</json:string><json:string>Inha University Hospital, Incheon, Korea The</json:string><json:string>National Taiwan University Hospital, Taipei, Taiwan</json:string><json:string>Okayama University Hospital, Okayama City, Japan Objectives</json:string><json:string>Duke University</json:string><json:string>Hospital Tuanku Jaafar/Kelab Sukan Hospital, Seremban</json:string><json:string>and Research Inc, Tulsa, OK, United States</json:string><json:string>Department of Rheumatology, China-Japan Friendship</json:string><json:string>Hospital of China Medical University, Shenyang, China Objective</json:string><json:string>Karolinska Institute and Karolinska Hospital, Stockholm, Sweden</json:string><json:string>Metroplex Clinical Research Center, University of Texas/Southwestern Medical Center, United States</json:string><json:string>Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Korea</json:string><json:string>AZMILLAH Hospital Selayang, Selangor, Malaysia Background</json:string><json:string>Hospital Selayang, Malaysia Methodology</json:string><json:string>In Turkey, AS</json:string><json:string>University of Pennsylvania</json:string><json:string>Hospital of Guangzhou University of Traditional Chinese Medcine</json:string><json:string>Tuen Mun Hospital, Hong Kong, China</json:string><json:string>Department of Medicine Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Seoul, Korea Background and Objective</json:string><json:string>Rheumatology Department, Hospital Tuanku Jaafar, Seremban, Malaysia Background</json:string><json:string>Mt Sinai Hospital, Toronto, ON, Canada</json:string><json:string>Kaken Pharmaceutical Co.</json:string><json:string>American College of Rheumatology</json:string><json:string>GUN Institute of Rheumatology Yokyo Women</json:string><json:string>Hospital, Shenyang, China</json:string><json:string>Rheumatology Department, Hospital Putrajaya, Putrajaya, Malaysia</json:string><json:string>Japan Tobacco Inc</json:string><json:string>Austria, University Hospital of Heraklion, Crete, Greece</json:string><json:string>Karolinska University Hospital, Stockholm, Sweden</json:string><json:string>Hospital Selayang, Malaysia</json:string><json:string>Territorial Clinical Hospital, Barnaul, Russian Federation</json:string><json:string>PAVELKA Institute of Rheumatology, Praha, Czech Republic Background</json:string><json:string>Omori Hospital Department Orthopaedics Surgery, Otaku Tokyo, Japan Aim</json:string><json:string>Malaysia AL LIM</json:string><json:string>Department of Rheumatology and Nephrology</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>K. Kawakami</json:string><json:string>Koichi</json:string><json:string>Asia Paci</json:string><json:string>Jung</json:string><json:string>A. Taniguchi</json:string><json:string>K. Ikari</json:string><json:string>To</json:string><json:string>MAO Deparment</json:string><json:string>Rebecca MacDonald</json:string><json:string>S. Momohara</json:string><json:string>La Jolla</json:string><json:string>Ji Won</json:string><json:string>K.K. M. Hara</json:string><json:string>Sinai Hosp</json:string></persName><placeName><json:string>TX</json:string><json:string>Leiden</json:string><json:string>Stanford</json:string><json:string>St Clair</json:string><json:string>Ankara</json:string><json:string>Philadelphia</json:string><json:string>San Diego</json:string><json:string>Malaysia</json:string><json:string>Rochester</json:string><json:string>Szczecin</json:string><json:string>Germany</json:string><json:string>United States</json:string><json:string>Dallas</json:string><json:string>Herne</json:string><json:string>Phila</json:string><json:string>Korea</json:string><json:string>Seoul</json:string><json:string>Poland</json:string><json:string>Beijing</json:string><json:string>Austria</json:string><json:string>Hong Kong</json:string><json:string>Nagoya</json:string><json:string>Turkey</json:string><json:string>ShenZhen</json:string><json:string>HIROSHIMA</json:string><json:string>Canada</json:string><json:string>Palo Alto</json:string><json:string>Boston</json:string><json:string>China</json:string><json:string>Shanghai</json:string><json:string>Toronto</json:string><json:string>Europe</json:string><json:string>Japan</json:string><json:string>Brussels</json:string><json:string>Leeds</json:string><json:string>Vienna</json:string><json:string>Tokyo</json:string><json:string>Incheon</json:string><json:string>United Kingdom</json:string><json:string>CA</json:string><json:string>MA</json:string><json:string>Malvern</json:string><json:string>MN</json:string><json:string>KANAZAWA</json:string><json:string>Belgium</json:string><json:string>Netherlands</json:string><json:string>Barnaul</json:string><json:string>PA</json:string><json:string>Craiova</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[1]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-G6MPTG3H-Z</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus></categories><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1111/j.1756-185X.2010.01498.x</json:string></doi><id>ABCA6AAAD9F3C6F09F7FA20152E8ECBB2ED9DBE6</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-G6MPTG3H-Z/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-G6MPTG3H-Z/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-G6MPTG3H-Z/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><licence>© 2010 Asia Pacific League of Associations for Rheumatology</licence></availability><date type="published" when="2010-07"></date></publicationStmt><notesStmt><note type="content-type" subtype="abstract" source="abstract" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="abstract"><analytic><title level="a" type="main">2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy</title><idno type="istex">ABCA6AAAD9F3C6F09F7FA20152E8ECBB2ED9DBE6</idno><idno type="ark">ark:/67375/WNG-G6MPTG3H-Z</idno><idno type="DOI">10.1111/j.1756-185X.2010.01498.x</idno><idno type="unit">APL1498</idno><idno type="toTypesetVersion">file:APL.APL1498.pdf</idno></analytic><monogr><title level="j" type="main">International Journal of Rheumatic Diseases</title><title level="j" type="sub">14th Congress of Asia Pacific League of Associations for Rheumatology, 11‐15 July 2010, Hong Kong Convention and Exhibition Centre</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES</title><idno type="pISSN">1756-1841</idno><idno type="eISSN">1756-185X</idno><idno type="book-DOI">10.1111/(ISSN)1756-185X</idno><idno type="book-part-DOI">10.1111/apl.2010.13.issue-s1</idno><idno type="product">APL</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">13</biblScope><biblScope unit="issue">s1</biblScope><biblScope unit="page" from="85">85</biblScope><biblScope unit="page" to="94">94</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2010-07"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-G6MPTG3H-Z/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley component found"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1756-185X</doi><issn type="print">1756-1841</issn><issn type="electronic">1756-185X</issn><idGroup><id type="product" value="APL"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES">International Journal of Rheumatic Diseases</title></titleGroup></publicationMeta><publicationMeta level="part" position="07000"><doi origin="wiley">10.1111/apl.2010.13.issue-s1</doi><titleGroup><title type="specialIssueTitle">14th Congress of Asia Pacific League of Associations for Rheumatology, 11‐15 July 2010, Hong Kong Convention and Exhibition Centre</title></titleGroup><numberingGroup><numbering type="journalVolume" number="13">13</numbering><numbering type="supplement">s1</numbering></numberingGroup><coverDate startDate="2010-07">July 2010</coverDate></publicationMeta><publicationMeta level="unit" type="abstract" position="13" status="forIssue"><doi origin="wiley">10.1111/j.1756-185X.2010.01498.x</doi><idGroup><id type="unit" value="APL1498"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="tocHeading1">14th Congress of Asia Pacific League of Associations for Rheumatology, 11‐15 July 2010, Hong Kong Convention and Exhibition Centre, APLAR 2010 Abstracts</title><title type="tocHeading2">Clinical Research</title></titleGroup><copyright>© 2010 Asia Pacific League of Associations for Rheumatology</copyright><eventGroup><event type="firstOnline" date="2010-06-20"></event><event type="publishedOnlineFinalForm" date="2010-06-20"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.9 mode:FullText source:Header result:Header" date="2010-06-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-23"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="85">85</numbering><numbering type="pageLast" number="94">94</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:APL.APL1498.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count></countGroup><titleGroup><title type="main">2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy</title></titleGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy</title></titleInfo><typeOfResource>text</typeOfResource><genre type="abstract" displayLabel="abstract" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2010-07</dateIssued><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">0</extent></physicalDescription><relatedItem type="host"><titleInfo><title>International Journal of Rheumatic Diseases</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1756-1841</identifier><identifier type="eISSN">1756-185X</identifier><identifier type="DOI">10.1111/(ISSN)1756-185X</identifier><identifier type="PublisherID">APL</identifier><part><date>2010</date><detail type="title"><title>14th Congress of Asia Pacific League of Associations for Rheumatology, 11‐15 July 2010, Hong Kong Convention and Exhibition Centre</title></detail><detail type="volume"><caption>vol.</caption><number>13</number></detail><detail type="issue"><caption>Suppl. no.</caption><number>s1</number></detail><extent unit="pages"><start>85</start><end>94</end><total>4</total></extent></part></relatedItem><identifier type="istex">ABCA6AAAD9F3C6F09F7FA20152E8ECBB2ED9DBE6</identifier><identifier type="ark">ark:/67375/WNG-G6MPTG3H-Z</identifier><identifier type="DOI">10.1111/j.1756-185X.2010.01498.x</identifier><identifier type="ArticleID">APL1498</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2010 Asia Pacific League of Associations for Rheumatology</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-G6MPTG3H-Z/record.json</uri></json:item></metadata><author></author><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002553 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002553 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:ABCA6AAAD9F3C6F09F7FA20152E8ECBB2ED9DBE6
|texte= 2.3. Rheumatoid arthritis ‐ anti‐TNFα therapy
}}
| This area was generated with Dilib version V0.6.33. |  |